TIGIT, a Novel Immune Checkpoint Therapy for Melanoma

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2023 Jul 26

PMID 37495610

Authors

Wei Tang

Jun Chen

Tianlong Ji

Xiufeng Cong

Affiliations

Soon will be listed here.

Abstract

Melanoma is the most aggressive and deadliest type of skin cancer. In the last 10 years, immune checkpoint blockades (ICBs) including PD-1/PD-L1 and CTLA-4 inhibitor has been shown to be effective against melanoma. PD-1/PD-L1 and CTLA-4 inhibitors have shown varying degrees of drug resistance in the treatment of melanoma patients. Furthermore, the clinical benefits of ICBs are also accompanied by severe immune toxicity. Therefore, there is an urgent need to develop new immune checkpoint inhibitors to optimize melanoma therapy and reduce cytotoxicity. T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) is thought to activate inhibitory receptors in T cells, natural killer (NK) cells, and regulatory T cells (Tregs), and has become a promising target for immunotherapy. Studies have found that TIGIT can be detected in different stages of melanoma, which is closely related to the occurrence, development, and prognosis of melanoma. This review mainly describes the immunosuppressive mechanism of TIGIT and its role in antitumor immunity of melanoma, so as to provide new ideas and schemes for the clinical treatment of melanoma with targeted TIGIT.

Citing Articles

Characterization of Exhausted T Cell Signatures in Pan-Cancer Settings.

Juthi R, Sazed S, Mareboina M, Zaravinos A, Georgakopoulos-Soares I Int J Mol Sci. 2025; 26(5).

PMID: 40076932 PMC: 11899893. DOI: 10.3390/ijms26052311.

Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response.

Liu L, Wu P, Wang B, Dong J, Zhang C, Liu W Cancer Immunol Immunother. 2025; 74(4):134.

PMID: 40035834 PMC: 11880484. DOI: 10.1007/s00262-025-03985-6.

Advances in Cell and Immune Therapies for Melanoma.

Timis T, Buruiana S, Dima D, Nistor M, Muresan X, Cenariu D Biomedicines. 2025; 13(1).

PMID: 39857682 PMC: 11761552. DOI: 10.3390/biomedicines13010098.

Modulation of Tumor-Associated Macrophages to Overcome Immune Suppression in the Hepatocellular Carcinoma Microenvironment.

Singer M, Zhang Z, Dayyani F, Zhang Z, Yaghmai V, Choi A Cancers (Basel). 2025; 17(1.

PMID: 39796695 PMC: 11718901. DOI: 10.3390/cancers17010066.

The endocannabinoid anandamide prevents TH17 programming of activated T lymphocytes while preserving TH1 responses.

Kiprina A, Teichmann T, Gimenez V, Xu W, Sailer F, Windbergs M Front Pharmacol. 2025; 15:1528759.

PMID: 39759451 PMC: 11695368. DOI: 10.3389/fphar.2024.1528759.

References

Han J, Khatwani N, Searles T, Turk M, Angeles C . Memory CD8 T cell responses to cancer. Semin Immunol. 2020; 49:101435. PMC: 7738415. DOI: 10.1016/j.smim.2020.101435. View

Lepletier A, Madore J, ODonnell J, Johnston R, Li X, McDonald E . Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clin Cancer Res. 2020; 26(14):3671-3681. DOI: 10.1158/1078-0432.CCR-19-3925. View

Ma J . Bioinformatics-guided analysis uncovers TIGIT as an epigenetically regulated immunomodulator affecting immunotherapeutic sensitivity of gastric cancer. Cancer Biomark. 2021; 33(3):349-358. DOI: 10.3233/CBM-210159. View

Chauvin J, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R . IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020; 26(20):5520-5533. PMC: 8045409. DOI: 10.1158/1078-0432.CCR-20-0575. View

Lee W, Lee Y, Choi M, Yun K, Won C, Lee M . Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes. J Am Acad Dermatol. 2019; 81(1):219-227. DOI: 10.1016/j.jaad.2019.03.012. View

Zhang J, Zhou X, Huang D, Luan C, Gu H, Ju M . Development of an Immune-Related Gene Signature for Prognosis in Melanoma. Front Oncol. 2021; 10:602555. PMC: 7874014. DOI: 10.3389/fonc.2020.602555. View

Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua J . DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. Cancers (Basel). 2019; 11(6). PMC: 6628015. DOI: 10.3390/cancers11060877. View

Reijers I, Menzies A, van Akkooi A, Versluis J, van den Heuvel N, Saw R . Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022; 28(6):1178-1188. DOI: 10.1038/s41591-022-01851-x. View

Such L, Zhao F, Liu D, Thier B, Le-Trilling V, Sucker A . Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020; 130(8):4266-4281. PMC: 7410049. DOI: 10.1172/JCI131572. View

10.

Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, Okita Y . Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 2010; 101(5):1326-30. PMC: 11158505. DOI: 10.1111/j.1349-7006.2010.01530.x. View

11.

Lozano E, Dominguez-Villar M, Kuchroo V, Hafler D . The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012; 188(8):3869-75. PMC: 3324669. DOI: 10.4049/jimmunol.1103627. View

12.

Murter B, Pan X, Ophir E, Alteber Z, Azulay M, Sen R . Mouse PVRIG Has CD8 T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity. Cancer Immunol Res. 2019; 7(2):244-256. PMC: 7038785. DOI: 10.1158/2326-6066.CIR-18-0460. View

13.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

14.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro B, OHalloran T . Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Clin Cancer Res. 2017; 23(8):1891-1897. PMC: 5392367. DOI: 10.1158/1078-0432.CCR-15-2240. View

15.

El-Sherbiny Y, Meade J, Holmes T, McGonagle D, Mackie S, Morgan A . The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007; 67(18):8444-9. DOI: 10.1158/0008-5472.CAN-06-4230. View

16.

Bernard P, Delconte R, Pastor S, Laletin V, Da Silva C, Goubard A . Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity. J Immunother Cancer. 2022; 10(5). PMC: 9121483. DOI: 10.1136/jitc-2021-004244. View

17.

Ge Z, Zhou G, Campos Carrascosa L, Gausvik E, Boor P, Noordam L . TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8 T Cells in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2021; 12(2):443-464. PMC: 8255944. DOI: 10.1016/j.jcmgh.2021.03.003. View

18.

Chiu D, Yuen V, Cheu J, Wei L, Ting V, Fehlings M . Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. Gastroenterology. 2020; 159(2):609-623. DOI: 10.1053/j.gastro.2020.03.074. View

19.

Fuhrman C, Yeh W, Seay H, Saikumar Lakshmi P, Chopra G, Zhang L . Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. J Immunol. 2015; 195(1):145-55. PMC: 4475416. DOI: 10.4049/jimmunol.1402381. View

20.

Levin S, Taft D, Brandt C, Bucher C, Howard E, Chadwick E . Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011; 41(4):902-15. PMC: 3733993. DOI: 10.1002/eji.201041136. View